Paper31136799
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.
McCune JS and 22 others. Biol Blood Marrow Transplant, 2019. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Papers, record 31136799. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31136799
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Busulfan | Major topic |
| Databases, Factual | Major topic |
| Drug Monitoring | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Registries | Major topic |
| Allografts | |
| Female | |
| Humans | |
| Male |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA033572 | NCI NIH HHS | United States | P30CA033572 | PubMed and NIH | NIH RePORTER |
| R01 CA182963 | NCI NIH HHS | United States | R01CA182963 | PubMed and NIH | NIH RePORTER |
| U54 HD083211 | NICHD NIH HHS | United States | U54HD083211 | PubMed and NIH | NIH RePORTER |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 32407883 | Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". | https://conductscience.org/library/papers/32407883 | PubMed |
| Comment in | 32531439 | Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". | https://conductscience.org/library/papers/32531439 | PubMed |
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10800058 | An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. | Bone Marrow Transplant | 2000 | https://conductscience.org/library/papers/10800058 | PubMed |
| 2 | 10976660 | Plasma concentration monitoring of busulfan: does it improve clinical outcome? | Clin Pharmacokinet | 2000 | https://conductscience.org/library/papers/10976660 | PubMed |
| 3 | 11148943 | A continuous-improvement approach for reducing the number of chemotherapy-related medication errors. | Am J Health Syst Pharm | 2000 | https://conductscience.org/library/papers/11148943 | PubMed |
| 4 | 11781609 | Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. | Bone Marrow Transplant | 2001 | https://conductscience.org/library/papers/11781609 | PubMed |
| 5 | 12149198 | Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. | Blood | 2002 | https://conductscience.org/library/papers/12149198 | PubMed |
| 6 | 12189535 | Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. | Bone Marrow Transplant | 2002 | https://conductscience.org/library/papers/12189535 | PubMed |
| 7 | 12595317 | HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. | Blood | 2003 | https://conductscience.org/library/papers/12595317 | PubMed |
| 8 | 16321161 | Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. | BMC Med Res Methodol | 2005 | https://conductscience.org/library/papers/16321161 | PubMed |
| 9 | 16332558 | The Delphi technique in health sciences education research. | Med Teach | 2005 | https://conductscience.org/library/papers/16332558 | PubMed |
| 10 | 16641398 | Hematopoietic stem-cell transplantation. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16641398 | PubMed |
| 11 | 18215782 | High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18215782 | PubMed |
| 12 | 18929686 | Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. | J Biomed Inform | 2009 | https://conductscience.org/library/papers/18929686 | PubMed |
| 13 | 19611402 | Busulfan in hematopoietic stem cell transplant setting. | Expert Opin Drug Metab Toxicol | 2009 | https://conductscience.org/library/papers/19611402 | PubMed |
| 14 | 22067636 | Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. | BMC Cancer | 2011 | https://conductscience.org/library/papers/22067636 | PubMed |
| 15 | 22198540 | Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. | Biol Blood Marrow Transplant | 2012 | https://conductscience.org/library/papers/22198540 | PubMed |
| 16 | 22742881 | Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. | Eur J Cancer | 2012 | https://conductscience.org/library/papers/22742881 | PubMed |
| 17 | 23581955 | Mass or molar? Recommendations for reporting concentrations of therapeutic drugs. | Med J Aust | 2013 | https://conductscience.org/library/papers/23581955 | PubMed |
| 18 | 23871781 | Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. | Biol Blood Marrow Transplant | 2013 | https://conductscience.org/library/papers/23871781 | PubMed |
| 19 | 24001695 | Harmonization of laboratory testing - Current achievements and future strategies. | Clin Chim Acta | 2014 | https://conductscience.org/library/papers/24001695 | PubMed |
| 20 | 24120352 | Promoting clinical and laboratory interaction by harmonization. | Clin Chim Acta | 2014 | https://conductscience.org/library/papers/24120352 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41904243 | Reduced relapse rate and improved GVHD/relapse free survival (GRFS) with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41904243 | PubMed |
| 41779961 | Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study. | Blood Adv | 2026 | https://conductscience.org/library/papers/41779961 | PubMed |
| 39932505 | New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis. | Cancer Chemother Pharmacol | 2025 | https://conductscience.org/library/papers/39932505 | PubMed |
| 39625679 | Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial. | Int J Hematol | 2025 | https://conductscience.org/library/papers/39625679 | PubMed |
| 39368808 | The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy. | Blood Adv | 2024 | https://conductscience.org/library/papers/39368808 | PubMed |
| 39271948 | A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT). | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/39271948 | PubMed |
| 39074263 | Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. | Blood Adv | 2024 | https://conductscience.org/library/papers/39074263 | PubMed |
| 37415003 | Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/37415003 | PubMed |
| 37379285 | Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation. | Blood Adv | 2023 | https://conductscience.org/library/papers/37379285 | PubMed |
| 36369996 | Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling. | Clin Pharmacol Ther | 2023 | https://conductscience.org/library/papers/36369996 | PubMed |
| 35330826 | Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand? | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35330826 | PubMed |
| 34956984 | Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. | Front Pediatr | 2021 | https://conductscience.org/library/papers/34956984 | PubMed |
| 34664209 | Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation. | Pharm Res | 2021 | https://conductscience.org/library/papers/34664209 | PubMed |
| 34453497 | Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. | CPT Pharmacometrics Syst Pharmacol | 2021 | https://conductscience.org/library/papers/34453497 | PubMed |
| 33128207 | Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. | Clin Pharmacokinet | 2021 | https://conductscience.org/library/papers/33128207 | PubMed |
| 32229032 | Using big data in pediatric oncology: Current applications and future directions. | Semin Oncol | 2020 | https://conductscience.org/library/papers/32229032 | PubMed |
| 32140913 | Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation. | Int J Clin Pharm | 2020 | https://conductscience.org/library/papers/32140913 | PubMed |
| 32077123 | Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning. | Br J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/32077123 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31136799
GET https://conductscience.org/api/papers/v1/31136799/authors?page=2